Delving into the Latest Updates on VAXON Biotech SA with Synapse

Overview

Tags

Neoplasms

Therapeutic vaccine

Biological products

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4

Top 5 Drug Type	Count

Therapeutic vaccine	3
Biological products	1

Top 5 Target	Count

HER2 x MAGEA1 x TERT	1
HER2 x HLA-A 24	1

Patients with histologically proven malignancy with documented disease control (objective response or stable disease) or Not Evaluable Disease (NED) expectancy > 6 months; only HLA-A*02 positive patients.
The primary objective of the trial is to compare safety and tolerability of four different doses of Vx-006. The secondary objective is to compare immunogenicity of four different doses of the Vx-006.

Start Date01 Mar 2014

Sponsor / Collaborator

VAXON Biotech SA

EUCTR2011-005968-24-CZ

/ Not yet recruitingPhase 2

A multicenter, randomized, double-blind, placebo-controlled Phase IIb Efficacy Study of Vx-001, a peptide-based cancer vaccine aimed to maintain disease control after first line treatment in HLA-A*0201 positive patients with TERT positive NSCLC (stage IV or recurrent stage I-III) - VaxLung

Start Date18 Dec 2013

Sponsor / Collaborator

VAXON Biotech SA

NCT01935154

/ CompletedPhase 2

Phase II Study of Vx001 Vaccine in HLA-A*0201 Positive Patients With TERT Positive Stage IV or Recurrent Stage I-III NSCLC

Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT expressing tumors will be included.
The objective of the trial is survival rate at 12 months.

Start Date01 Aug 2012

Sponsor / Collaborator

VAXON Biotech SA

100 Clinical Results associated with VAXON Biotech SA

Login to view more data

0 Patents (Medical) associated with VAXON Biotech SA

Login to view more data

2

Literatures (Medical) associated with VAXON Biotech SA

STP Pharma Pratiques

Le cahier de laboratoire électronique (CLE)

Author: Alain Malpertuy ; Jeanne Menez Jamet ; Christophe Blanchet ; Céline Baczynski ; Céline Rouger ; Emmanuelle Dorlanne-Messiaen ; Eric Grognard ; Anabelle Amiard ; Ivan Racle ; Alexandre De Brevern ; Galina Kisselova

The laboratory notebook is an essential tool in the company and in the laboratory. It allows durable follow-up of experiments; it is also an essential legal tool. Its electronic versions have become increasingly efficient over recent years, providing new functions, more rapid access to data and aid to decision-making, but they also raise new questions concerning their ease of use and their possible limitations. This article is designed to summarize the specificities and advantages of the electronic laboratory notebook as well as its current limitations.

IDrugs

Development of optimized cryptic peptides for immunotherapy

Author: Kosmatopoulos, Kostas ; Menez-Jamet, Jeanne

A review.Specific immunotherapy is based on the use of tumor-specific antigens to induce an efficient antitumor immune response.Although tumors are known to be weakly immunogenic and therefore capable of escaping immune surveillance, the objective of tumor vaccination is to induce a frequent, strong and long-lasting antitumor immune response based mainly on the activation of cytotoxic T-lymphocytes.However, as widely expressed tumor antigens (universal tumor antigens) often correspond to normal proteins expressed not only by tumor cells but also by normal cells and tissues, these antigens are generally tolerated by the immune system.Thus, circumventing self tolerance to universal tumor antigens is a major goal of cancer vaccine research.Disappointing results obtained to date with most tumor vaccines has led to a shift in research toward determining ways of stimulating the immune response through the use of new adjuvants, immunostimulants and delivery vectors.However, although these aspects are clearly crucial to vaccine development, breakthroughs in the field may lie in the use of strong antigens as optimized cryptic peptides derived from universal tumor antigens, combined with a potent adjuvant.Targeting cryptic tumor peptides/antigens is an efficient way of overcoming tolerance.Indeed, the first vaccine based on an optimized cryptic peptide induced strong antitumor immunity and demonstrated promising clin. activity.

2

News (Medical) associated with VAXON Biotech SA

07 May 2021

·www.globenewswire.com

Worldwide Peptide Cancer Vaccine Industry to 2026 - 90

Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. As per this reports findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. Report Highlights: The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer. The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers. Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries. Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells. Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry. Key Topics Covered: 1. Introduction to Peptide Cancer Vaccine 2. Need of Peptide Vaccines2.1 Why Peptides - More Desirable2.2 Peptide Vaccines V/S Traditional Vaccines 3. Classification of Peptide Vaccines3.1 On the Basis of Sources Obtained3.2 On the Basis of Length3.3 On the Basis of Epitopes 4. Mechanism of Action of Peptide Cancer Vaccines4.1 Immunological Cells Activated by Peptide Cancer Vaccines4.2 Procedure of Synthetic Peptide Vaccine Development 5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia5.1 Basic Layout of the Study5.2 Introduction to WT1 Peptide5.3 Methodologies Involved In the Clinical Study5.4 Results of the Clinical Trial Study 6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer6.1 Colorectal Cancer6.2 Lung Cancer6.3 Pancreatic Cancer6.4 Gastric Cancer6.5 Prostate Cancer6.6 Breast Cancer 7. Global Peptide Cancer Vaccine Market Overview 8. Global Peptide Cancer Vaccine Market Trends8.1 Optimized Cryptic Peptides8.2 Therapeutic CpG Peptide-Based Cancer Vaccine8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides8.4 Recombinant Peptide Vaccine8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines 9. Global Peptide Cancer Vaccine Pipeline Overview9.1 By Country9.2 By Company9.3 By Patient Segment9.4 By Phase 10. Global Peptide Cancer Vaccine Clinical Trials Insight10.1 Research10.2 Preclinical10.3 Phase-I10.4 Phase-I/II10.5 Phase-II10.6 Phase-III 11. LucaVax - First Commercially available Peptide Cancer Vaccine 12. Global Peptide Cancer Vaccine Market Dynamics12.1 Market Driving Factors12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development 13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy 14. Competitive Landscape14.1 Enzo Life Science (Alexis Biotech)14.2 Antigen Express14.3 BioLife Science14.4 Immatics Biotechnologies14.5 Immune Design14.6 Imugene14.7 Immunomedics14.8 ISA Pharmaceuticals14.9 Galena Biopharma14.10 Generex Biotechnology Corporation14.11 Lytix Biopharma14.12 Merck (Merck Serono)14.13 OncoTherapy Science14.14 Oncothyreon14.15 Pfizer14.16 Phylogica14.17 Symphogen (Receptor BioLogix)14.18 Sumitomo Dainippon Pharma14.19 TapImmune14.20 Vaxon Biotech For more information about this report visit

VaccineImmunotherapy

07 May 2021

·www.globenewswire.com

Worldwide Peptide Cancer Vaccine Industry to 2026 - 90 Peptide Vaccines in Pipeline with Market Opportunity Value of >$20 Billion

Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "Global Peptide Cancer Vaccine Market & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering. As per this reports findings, it is estimated that the global peptide cancer vaccine will follow trajectory growth rates. The market will be favored by the advancement in science and arrival of novel technologies which will further enable the identification of potential targets in developing cancer vaccines. Report Highlights: The developments of vaccines have shown incredible impact on human health system and have resulted in significant decrease in mortality rates from several diseases. Increase in prevalence of chronic disorders including cancer has urged the development of novel targeted therapeutics for their management. In recent times, researchers have exploited the use of vaccines to generate anti-tumor response in management of cancer. The rapid approval of Provenge for the management of pancreatic cancer and the robust response in market has surged the development of more targeted vaccines in cancer. In recent times, peptides have emerged as a potential vaccine candidate owing to their small size, simple and cost efficient production and development process. Moreover, peptides are recognized to be highly specific and efficacious, safe and well tolerated. Given their attractive physical and chemical properties, researchers have developed several peptide based vaccines in management of wide range of cancers. Currently, GV1001 (Riavaxtm, Tertomotide) is the only peptide based vaccine approved for the management of pancreatic cancer in Korea. GV1001 is a 16-amino-acid peptide comprising a sequence from the human enzyme telomerase reverse transcriptase (TERT). Most cancers highly express TERT, and immunization with GV1001 aims to activate the immune system to recognize and kill cancer cells. The vaccine is currently under clinical trials and applications to gain approval in other countries. Apart from this, a cocktail of peptide based cancer vaccines are present in preclinical and clinical studies and have shown encouraging response. Most of the drugs are present in the phase I and II clinical trials which suggests that the market will be flourished with several vaccines targeting different cancers in next 4-5 years. Moreover, in near future the market will see combination of vaccines along with other conventional drugs to improve their efficacy and specificity in targeting the complexity of cancer cells. Keeping in mind the high adoption rates of the novel therapeutics in North America, it is expected that the region will dominate the global peptide cancer vaccine market for next few years. The high prevalence of cancer and the rising initiatives by government as well as private sectors will also propel the growth of peptide cancer vaccines in this area. In addition to this, Europe and Asia Pacific will also emerge as a potential market wing to high untapped opportunities, low cost of raw material, growing base of companies providing outsourcing services, flourishing biotech industry, and increasing investments in the R&D sector. The arrival of peptide based cancer vaccine has caused prompting effects on the overall cancer therapy market and has helped it to make through all the challenges that have been on the way of becoming the most dominant market in the industry. Key Topics Covered: 1. Introduction to Peptide Cancer Vaccine 2. Need of Peptide Vaccines2.1 Why Peptides - More Desirable2.2 Peptide Vaccines V/S Traditional Vaccines 3. Classification of Peptide Vaccines3.1 On the Basis of Sources Obtained3.2 On the Basis of Length3.3 On the Basis of Epitopes 4. Mechanism of Action of Peptide Cancer Vaccines4.1 Immunological Cells Activated by Peptide Cancer Vaccines4.2 Procedure of Synthetic Peptide Vaccine Development 5. Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein against Acute Myeloid Leukemia5.1 Basic Layout of the Study5.2 Introduction to WT1 Peptide5.3 Methodologies Involved In the Clinical Study5.4 Results of the Clinical Trial Study 6. Wide Spectrum Action of Peptide Cancer Vaccines Against Major Cancer6.1 Colorectal Cancer6.2 Lung Cancer6.3 Pancreatic Cancer6.4 Gastric Cancer6.5 Prostate Cancer6.6 Breast Cancer 7. Global Peptide Cancer Vaccine Market Overview 8. Global Peptide Cancer Vaccine Market Trends8.1 Optimized Cryptic Peptides8.2 Therapeutic CpG Peptide-Based Cancer Vaccine8.3 Personalized Neoantigen Vaccination with Synthetic Long Peptides8.4 Recombinant Peptide Vaccine8.5 p53 Peptide-Pulsed Dendritic Cells Cancer Vaccines 9. Global Peptide Cancer Vaccine Pipeline Overview9.1 By Country9.2 By Company9.3 By Patient Segment9.4 By Phase 10. Global Peptide Cancer Vaccine Clinical Trials Insight10.1 Research10.2 Preclinical10.3 Phase-I10.4 Phase-I/II10.5 Phase-II10.6 Phase-III 11. LucaVax - First Commercially available Peptide Cancer Vaccine 12. Global Peptide Cancer Vaccine Market Dynamics12.1 Market Driving Factors12.2 Challenges Ahead For Peptide Cancer Vaccine Market Development 13. Peptide Cancer Vaccine: Promising Candidate of Cancer Immunotherapy 14. Competitive Landscape14.1 Enzo Life Science (Alexis Biotech)14.2 Antigen Express14.3 BioLife Science14.4 Immatics Biotechnologies14.5 Immune Design14.6 Imugene14.7 Immunomedics14.8 ISA Pharmaceuticals14.9 Galena Biopharma14.10 Generex Biotechnology Corporation14.11 Lytix Biopharma14.12 Merck (Merck Serono)14.13 OncoTherapy Science14.14 Oncothyreon14.15 Pfizer14.16 Phylogica14.17 Symphogen (Receptor BioLogix)14.18 Sumitomo Dainippon Pharma14.19 TapImmune14.20 Vaxon Biotech For more information about this report visit

VaccineImmunotherapy

100 Deals associated with VAXON Biotech SA

Login to view more data

100 Translational Medicine associated with VAXON Biotech SA

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Phase 1 Clinical

1

Phase 2 Clinical

Other

3

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Vx-006 ( HER2 x MAGEA1 x TERT )	Neoplasms More	Phase 2
Vbx-016	Neoplasms More	Phase 1 Clinical
Vbx-021	Neoplasms More	Preclinical
Vbx-026 ( HER2 x HLA-A 24 )	Neoplasms More	Discovery
Vx-001 ( TERT )	metastatic non-small cell lung cancer More	Pending